Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
GHRP-2
Also known as: Growth Hormone Releasing Peptide 2, Pralmorelin, KP-102
GHRP-2 is a synthetic hexapeptide growth hormone secretagogue that produces a strong, dose-dependent GH release. It is approved in Japan as a diagnostic agent for GH deficiency under the name Pralmorelin. It is considered one of the most potent GHRPs but also raises cortisol and prolactin more than Ipamorelin.
Risk Level
Medium RiskDifficulty
Intermediate| CAS Number | 158861-67-7 |
| Molecular Formula | C45H55N9O6 |
| Class | Peptide |
| Category | Well-Known Peptides |
Mechanism of Action
GHRP-2 activates the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, stimulating GH release through a mechanism distinct from GHRH. It also suppresses somatostatin tone, allowing for amplified GH pulses when combined with GHRH analogs. Additionally, it moderately stimulates ACTH and cortisol release and increases prolactin levels, indicating broader receptor activity compared to more selective GHRPs.
Dosing Research
Research dosing is typically 100-300 mcg subcutaneously 2-3 times daily, administered on an empty stomach. Saturation dose is approximately 100 mcg; doses above 200 mcg show diminishing returns for GH release. Often combined with a GHRH analog for synergistic effects.
Side Effects & Risks
Increased appetite is a notable effect due to ghrelin receptor activation. Elevations in cortisol and prolactin occur at higher doses and may be clinically relevant with chronic use. Water retention, drowsiness, and tingling or numbness in extremities are also reported.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.